Antiepileptic Drug Interactions

  • E. Perucca
  • A. Richens
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 74)


Antiepileptic drug interactions may be either pharmacokinetic or pharmacodynamic; this chapter discusses only the former. Due to the difficulties of extrapolating animal data to the clinical situation, this review will be restricted to studies which have been performed in normal human volunteers or in patients. Reference to animal experiments, however, will be made occasionally when these are considered to be particularly relevant to the interpretation of clinical findings.


Valproic Acid Plasma Protein Binding Epileptic Patient Oral Contraceptive Steroid Plasma Protein Binding Site 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abernethy D R, Greenblatt D J, Divoll M, Arendt R, Ochs H R, Shader R I (1982) Impairment of diazepam metabolism by low-dose estrogen-containing oral contraceptive steroids. N Engl J Med 306: 791–792PubMedCrossRefGoogle Scholar
  2. Acocella G, Bonollo L, Mainardi M, Margardoli P (1974) Kinetic studies on rifampicin. III. Effect of phenobarbital on the half-life of the antibiotic. Tijdschr Gastroenterol 17: 151–158Google Scholar
  3. Ahmad S (1974) Renal insensitivity to frusemide caused by chronic anticonvulsant therapy. Br Med J 3: 657–659PubMedCrossRefGoogle Scholar
  4. Ahmad S, Clarke L, Hewett AJ, Richens A (1976) Controlled trial of frusemide as an antiepileptic drug in focal epilepsy. Clin Pharmacokinet 3: 621–625Google Scholar
  5. Aitio M L, Vuorenmaa T (1980) Enhanced metabolism and diminished efficacy of diso-pyramide by enzyme-induction. Br J Clin Pharmacol 9: 149–152PubMedGoogle Scholar
  6. Aitio M L, Mansbury L, Tala E, Haataja M, Aitio A (1981) The effect of enzyme induction on the metabolism of disopyramide in man. Br J Clin Pharmacol 11: 279–286PubMedGoogle Scholar
  7. Alexanderson B, Price-Evans D A, Sjoqvist F (1969) Steady-state levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 4: 764–768PubMedCrossRefGoogle Scholar
  8. Alvan G, Piafsky K, Lind N, Von Bahr C (1977) Effect of pentobarbital on the disposition of alprenolol. Clin Pharmacol Ther 22: 316–321PubMedGoogle Scholar
  9. Andreasen P B, Froland A, Skovsted L, Andersen S A, Hauge M (1973) Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: the role of genetic factors. Acta Med Scand 193: 561–564PubMedCrossRefGoogle Scholar
  10. Back D J, Breckenridge A M, Crawford F E, Maclver O, Orme Ml’E, Perucca E, Richens A, Rowe P H, Smith E (1980) The effect of oral contraceptive steroids and enzyme-inducing drugs on sex hormone binding globulin capacity in women. Br J Clin Pharmacol 9: 115 PGoogle Scholar
  11. Back D J, Bates M, Breckenridge A M, Ellis A, Hall J M, Maclver M, Orme Ml’E, Rowe P H (1981 a) The in vitro metabolism of ethinyloestradiol, mestranol and levonorgestrel by human jejunal mucosa. Br J Clin Pharmacol 11: 275–278Google Scholar
  12. Back D J, Bates M, Bowden A, Breckenridge A M, Hall M J, Jones H, Maclver M, Orme Ml’E, Perucca E, Richens A, Rowe P H, Smith E (1981 b) The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 22: 495–503Google Scholar
  13. Ballek R E, Reidenberg M M, Orr L (1973) Inhibition of diphenylhydantoin metabolism by chloramphenicol. Lancet 1:150 Ballinger B R, Prealy A, Reid A H, Stevenson I H (1974) The effects of hypnotics on imipramine treatment. Psychopharmacology 39: 267–274Google Scholar
  14. Barragry J M, Makin H L J, Trafford D J H, Scott D F (1978) Effect of anticonvulsants on plasma testosterone and sex hormone binding globulin levels. J Neurol Neurosurg Psychiatry 41: 913–914PubMedCrossRefGoogle Scholar
  15. Bauer L A (1982) Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 32: 570–572PubMedGoogle Scholar
  16. Baylis E M, Croley J M, Preece J M, Sylvester P E, Marks V (1971) Influence of folic acid on blood phenytoin levels. Lancet 1: 62–64PubMedCrossRefGoogle Scholar
  17. Begg E J, Chinwah P M, Webb C, Day R O, Wade D N (1982) Enhanced metabolism of mexiletine after phenytoin administration. Br J Clin Pharmacol 14: 219–223PubMedGoogle Scholar
  18. Bielmann I, Luac T, Gagnon M A (1978) Clonazepam: its efficacy in association with phenytoin and phenobarbital in mental patients in generalized major motor seizures. Int J Clin Pharmacol 16: 268–273Google Scholar
  19. Block S H (1982) Carbamazepine-isoniazid interaction. Pediatrics 69: 494–495PubMedGoogle Scholar
  20. Bloxham R A, Durbin G M, Johnson T, Winterborn M H (1979) Chloramphenicol and phenobarbitone - a drug interaction. Arch Dis Child 54: 76PubMedCrossRefGoogle Scholar
  21. Bochner F, Hooper W D, Tyrer J H, Eadie M J (1972) Factors involved in an outbreak of phenytoin intoxication. J Neurol Scand 16: 481–487CrossRefGoogle Scholar
  22. Bogaert M G, Rosseel M T, Belpaine F M (1971) Metabolism of nitroglycerine in man: influence of phenobarbital. Arch Int Pharmacodyn Ther 24: 1303–1311Google Scholar
  23. Bollini P, Riva R, Albani F, Ida N, Cacciari L, Bollini C, Baruzzi A (1983) Decreased phenytoin level during antineoplastic therapy: a case report. Epilepsia 24: 75–78PubMedCrossRefGoogle Scholar
  24. Borga O, Azarnoff D L, Forshell G P, Sjoqvist F (1969) Plasma protein binding of tricyclic antidepressants in man. Biochem Pharmacol 18: 2135–2143PubMedCrossRefGoogle Scholar
  25. Bourgeois B F D, Dodson W E, Ferrendelli J A (1982) Interactions between primidone, carbamazepine and nicotinamide. Neurology 32: 1122–1126PubMedGoogle Scholar
  26. Bowdle T A, Levy R H, Cutler R E (1979) Effect of carbamazepine on valproic acid kinetics in normal subjects. Clin Pharmacol Ther 26: 629–634PubMedGoogle Scholar
  27. Boylan J J, Owen D S, Chin J B (1976) Phenytoin interference with dexamethasone. JAMA 235: 803–804PubMedCrossRefGoogle Scholar
  28. Braithwaite R A, Flanagan R A, Richens A (1975) Steady-state plasma nortriptyline concentrations in epileptic patients. Br J Clin Pharmacol 2: 469–471PubMedGoogle Scholar
  29. Brennan R W, Dehejia H, Kutt H, Verebely K, McDowell F (1970) Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid. Neurology 20: 687–693PubMedGoogle Scholar
  30. Brooks S M, Werk E E, Ackerman S J, Sullivan I, Thrasher K (1972) Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 286: 1125–1128PubMedCrossRefGoogle Scholar
  31. Brooks P M, Buchanan W W, Grove M, Downie N W (1976) Effects of enzyme-induction on metabolism of prednisolone. Clinical and laboratory study. Ann Rheum Dis 35: 339–343Google Scholar
  32. Brown J E, Kitchell B B, Bjornsson T D, Shand D G (1981) The artifactual nature of heparin-induced drug binding alteration. Clin Pharmacol Ther 30: 636–643PubMedCrossRefGoogle Scholar
  33. Bruni J, Gallo J M, Lee C S, Perchalski R J, Wilder B J (1980 a) Interactions of valproic acid with phenytoin. Neurology 30: 1233–1236Google Scholar
  34. Bruni J, Wilder B J, Perchalski R J, Hammond E J, Villareal H J (1980 b) Valproic acid and plasma levels of phenobarbital. Neurology 30: 94–97Google Scholar
  35. Busfield D, Child K J, Atkinson R M, Tomich E G (1963) An effect of phenobarbitone on blood levels of griseofulvin in man. Lancet II: 1042Google Scholar
  36. Chapron D J, Kramer P A, Mariano S L, Hohnadel D C (1979 a) Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol 36: 436–438Google Scholar
  37. Chapron D J, Numford D, Pitegoff G I ( 1979 b) Apparent quinidine-induced digoxin toxicity after withdrawal of pentobarbital. Case of sequential drug interactions. Arch Intern Med 139: 363–364Google Scholar
  38. Christensen L K, Skovsted L (1969) Inhibition of drug metabolism by chloramphenicol. Lancet II: 1397–1399Google Scholar
  39. Cloyd J C, Miller K W, Leppik I E (1981) Primidone kinetics: effects of concurrent drugs and duration of therapy. Clin Pharmacol Ther 29: 402–407PubMedCrossRefGoogle Scholar
  40. Collste P, Seideman P, Borg K O, Haglund K, Von Bahr C (1979) Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol. Clin Pharmacol Ther 25: 423–127PubMedGoogle Scholar
  41. Coulam C B, Annegers J F (1979) Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 20: 519–526PubMedCrossRefGoogle Scholar
  42. Cramer J A, Mattson R H (1979) Valproic acid: in vitro plasma protein binding and interaction with phenytoin. Ther Drug Monit 1: 105–116PubMedCrossRefGoogle Scholar
  43. Cunningham J L, Price-Evans D A (1981) Acetanilide and paracetamol pharmacokinetics before and after phenytoin administration: genetic control of induction. Br J Clin Pharmacol 11: 591–596PubMedGoogle Scholar
  44. Dahlqvist R, Borgå O, Rane A, Walsh Z, Sjoqvist F (1979) Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol 8: 547–552PubMedGoogle Scholar
  45. Dam M, Jensen A, Christiansen J (1975) Plasma level and effect of carbamazepine in grandGoogle Scholar
  46. mal and psychomotor epilepsy. Acta Neurol Scand [Suppl] 60:33–38Google Scholar
  47. Dam M, Kristensen C B, Hansen B S, Christiansen J (1977) Interaction between carbamazepine and propoxyphene in man. Acta Neurol Scand 56: 603–607PubMedCrossRefGoogle Scholar
  48. Dana-Haeri J, Richens A (1981) Effect of antiepileptic drugs on the hypothalamic pituitary axis. Br Med J 282: 902CrossRefGoogle Scholar
  49. Data J L, Wilkinson G R, Nies A S (1976) Interaction of quinidine with anticonvulsant drugs. N Engl J Med 294: 699–702PubMedCrossRefGoogle Scholar
  50. De Rautlin de La Roy Y, Beauchant G, Breuil K, Patte F (1971) Diminution du taux sérique de rifampicine par le phenobarbital. Presse Med 79: 350Google Scholar
  51. Desmond P V, Roberts R K, Wilkinson G R, Wood A J J, Dunn D, Schenker S (1979) The effect of heparin on benzodiazepine binding. Fed Proc 38: 743Google Scholar
  52. Dhillon S, Richens A (1981 a) Pharmacokinetics of diazepam in epileptic patients and normal volunteers following intravenous administration. Br J Clin Pharmacol 12: 841–844Google Scholar
  53. Dhillon S, Richens A (1981 b) Serum protein binding of diazepam and its displacement by valproic acid in vitro. Br J Clin Pharmacol 12: 591–592Google Scholar
  54. Dhillon S, Richens A (1982) Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol 13: 553–560PubMedGoogle Scholar
  55. Dravet C, Mesdjan E, Cenraud B, Roger J (1977) Interaction between carbamazepine and triacetyloleandomycin. Lancet 1: 810–811PubMedCrossRefGoogle Scholar
  56. Editorial (1980) Drug interactions with oral contraceptive steroids. Br Med J 281: 93–94CrossRefGoogle Scholar
  57. Eichelbaum M, Kothe K W, Hoffmann F, Von Unruh G E (1979) Kinetics and metabolism of carbamazepine during combined antiepileptic therapy. Clin Pharmacol Ther 26: 367–371Google Scholar
  58. Fincham R W, Schottelius D D (1979) Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit 1: 277–283PubMedCrossRefGoogle Scholar
  59. Fincham R W, Schottelius D D, Sahs AL (1974) The influence of diphenylhydantoin on primidone metabolism. Arch Neurol 30: 259–262PubMedGoogle Scholar
  60. Fincham R W, Wiley D E, Schottelius D D (1976) Use of phenytoin serum levels in a case of status epilepticus. Neurology 26: 879–881PubMedGoogle Scholar
  61. Fine A, Henderson I S, Morgan D R, Tilstone W J (1977) Malabsorption of frusemide caused by phenytoin. Br Med J 2: 1061–1062PubMedCrossRefGoogle Scholar
  62. Finelli PF (1976) Phenytoin and methadone tolerance. N Engl Med 294: 110Google Scholar
  63. Flachs H, Gram L, Wiirtz-Jorgensen A, Parnas J (1979) Drug levels of other antiepileptic drugs during concomitant treatment with sodium valproate. Epilepsia 20: 187Google Scholar
  64. Fleitman J S, Bruni J, Perrin J H, Wilder B J (1980) Albumin-binding interactions of sodium valproate. J Clin Pharmacol 20: 514–517PubMedGoogle Scholar
  65. Frantzen E, Hansen J M, Hansen O E, Kristensen M (1967) Phenytoin (Dilantin®) intoxication. Acta Neurol Scand 43: 440–446PubMedCrossRefGoogle Scholar
  66. Fraser D G, Ludden T M, Evens R P, Sutherland E W III (1980): Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther 27: 165–169PubMedCrossRefGoogle Scholar
  67. Friel P N, Leal K W, Wilensky A J (1979) Valproic acid-phenytoin interaction. Ther Drug Monit 1: 243–248PubMedCrossRefGoogle Scholar
  68. Frigo G M, Lecchini S, Caravaggi M, Gatti G, Tonini M, D’Angelo L, Perucca E, Crema A (1983) Reduction in phenytoin clearance caused by cimetidine. Eur J Clin Pharmacol 25: 135–137PubMedCrossRefGoogle Scholar
  69. Fuji K, Hayashi M, Murata R (1975) Effect of diphenylhydantoin therapy on plasma 11-OHCS: interference in the effects of dexamethasone and metapirone. Brain Dev 7: 354–360Google Scholar
  70. Furlanut M, Rizzoni G (1980) Effetti del dipropilacetato sulla cinetica della antipirina (Abstr). Proceedings 20th Meeting of the Italian Pharmacological Society ( SIF ), VeronaGoogle Scholar
  71. Furlanut M, Benetello P, Avogaro A, Dainese R (1978) Effects of folic acid on phenytoin kinetics in healthy subjects. Clin Pharmacol Ther 24: 294–297PubMedGoogle Scholar
  72. Gangji D, Schwade JG, Strong J M (1980) Phenytoin-misonidazole: a possible metabolic interaction. Cancer Treat Rep 64: 155–156PubMedGoogle Scholar
  73. Garratt W R, Carter B L, Pellock JM (1979) Bioavailability of phenytoin administered with antacids. Ther Drug Monit 1: 435–437CrossRefGoogle Scholar
  74. Garrettson L K, Perel J M, Dayton P G (1969) Methylphenidate interaction with both anticonvulsants and ethyl-biscoumacetate. JAMA 207: 2053–2056PubMedCrossRefGoogle Scholar
  75. Geaney D P, Carver J G, Davies C L, Aronson J K (1983) Pharmacokinetic investigation of the interaction of azapropazone with phenytoin. Brit J Clin Pharmacol 15: 727–734Google Scholar
  76. Giacomini K, Giacomini J, Blaschke T (1980) Heparin decreases plasma protein binding of drugs. Clin Pharmacol Ther 27: 256CrossRefGoogle Scholar
  77. Goldberg MJ, Berlinger WG (1982) Treatment of phenobarbital overdose with activated charcoal. JAMA 247: 2400–2401PubMedCrossRefGoogle Scholar
  78. Greenblatt D J, Shader R I, Harmatz J S, Franke K, Koch-Weser J (1976) Influences of magnesium and aluminium hydroxide mixture on chlordiazepoxide absorption. Clin Pharmacol Ther 19: 234–239PubMedGoogle Scholar
  79. Gugler R, Von Unrhuh G E (1980) Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 5: 67–83PubMedCrossRefGoogle Scholar
  80. Gupta S (1982) Phenobarbital and metabolism of metronidazole. N Engl J Med 308: 529Google Scholar
  81. Haglund K, Seideman P, Collste B, Borg K O, Von Bahr C (1979) Influence of pentobarbital on metroprolol plasma levels. Clin Pharmacol Ther 26: 326–329PubMedGoogle Scholar
  82. Hahn T J (1976) Bone complications of anticonvulsants. Drugs 12: 210–211CrossRefGoogle Scholar
  83. Hammer W, Idestrom C M, Sjoqvist F (1967) Chemical control of antidepressant drug therapy. Minerva Med Int Congr Ser 122: 301–310Google Scholar
  84. Hancock K W, Levell M J (1978) Primidone/dexamethasone interaction. Lancet 11: 97–98CrossRefGoogle Scholar
  85. Hansen J M, Kristensen M, Skovsted L, Christensen L K (1966) Dicoumarol-induced diphenylhydantoin intoxication. Lancet 11: 265–266CrossRefGoogle Scholar
  86. Hansen JM, Kristensen M, Skovsted L (1968) Sulthiame (Ospolot®) as inhibitor of diphenylhydantoin metabolism. Epilepsia 9: 17–22Google Scholar
  87. Hansen J M, Siersbaek-Nielsen K, Kristensen M, Skovsted L, Christensen L K (1971 a) Effect of diphenylhydantoin on the metabolism of dicoumarol in man. Acta Med Scand 189: 15–19Google Scholar
  88. Hansen J M, Siersbaek-Nielsen K, Skovsted L (1971b) Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 12: 539–543PubMedGoogle Scholar
  89. Hansen J M, Kampmann J P, Siersbaek-Nielsen K, Lumholtz I B, Arroe M, Abilgaard V, Skovsted L (1979) The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand [Suppl] 624: 106–110Google Scholar
  90. Hansen B S, Dam M, Brandt J, Hvidberg E F, Angelo H, Christensen J M, Lous P (1980 a) Influence of dextropropoxyphene on steady-state serum levels and protein binding of three antiepileptic drugs. Acta Neurol Scand 61: 357–367Google Scholar
  91. Hansen J M, Busk G, Niemi G, Haase N J, Lumholtz B, Skovsted L, Kampmann JP ( 1980 b) Inhibition of phenytoin metabolism by sulfinpyrazone (Abstr 0584 ). In: Turner P, Padgham C (eds) Abstracts of the world conference on clinical pharmacology and therapeutics, London. MacMillan, LondonGoogle Scholar
  92. Hansten P D (1973) Drug interactions. Lea and Febiger, Philadelphia Hayes S L, Pablo G, Radomski T, Palmer R F (1977) Ethanol and oral diazepam absorption. N Engl J Med 296: 186–189Google Scholar
  93. Hedrick R, Williams F, Morin R, Lamb W A, Cate J C IV (1983) Carbamazepine-erythromycin interaction leading to carbamazepine toxicity in four epileptic children. Ther Drug Monit 5: 405–407Google Scholar
  94. Heijertz R, Pilz H (1978) Interaction of nitrofurantoin with diphenylhydantoin. J Neurol 218: 297–301CrossRefGoogle Scholar
  95. Hempel E, Klinger W (1976) Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications. Drugs 12: 442–448PubMedCrossRefGoogle Scholar
  96. Hendeles L (1979) Decreased oral phenytoin absorption following concurrent theophylline administration. J Allergy Clin Immunol 63: 156Google Scholar
  97. Herishanu Y, Eylath U, Ilan R (1976) Effect of calcium content of diet on absorption of diphenylhydantoin. Israel J Med Sci 12: 1453–1456PubMedGoogle Scholar
  98. Hetzel D J, Bochner F, Hallpike J F, Sherman D J C, Hann C S (1981) Cimetidine interaction with phenytoin. Br Med J 282: 1512CrossRefGoogle Scholar
  99. Hewick D S, Sparks R G, Stevenson I H, Watson I D (1977) Induction of imipramine metabolism following barbiturate administration. Br J Clin Pharmacol 4: 399Google Scholar
  100. Hooper W O, Sutherland J M, Bochner F, Tyrer J G, Eadie M J (1971) The effect of certain drugs on the plasma protein binding of diphenylhydantoin. Aust NZ J Med 3: 377–381CrossRefGoogle Scholar
  101. Houghton G W, Richens A (1974 a) Phenytoin intoxication induced by sulthiame in epileptic patients. J Neurol Psychiatry 37: 275–281Google Scholar
  102. Houghton G W, Richens A (1974 b) Inhibition of phenytoin metabolism by sulthiame in epileptic patients. Br J Clin Pharmacol 1: 59–66Google Scholar
  103. Huisman J W, van Heycop Ten Ham M W, van Zijl C H W (1970) Influence of ethyl-phenacemide on serum levels of other antiepileptic drugs. Epilepsia 11: 207–215Google Scholar
  104. Hurwitz A (1977) Antacid therapy and drug kinetics. Clin Pharmacol 2: 269–280CrossRefGoogle Scholar
  105. Jao J Y, Jusko W J, Cohen J L (1972) Phenobarbital effects on cyclophosphamide pharmacokinetics. Cancer Res 32: 2761–2764PubMedGoogle Scholar
  106. Jelliffe R W, Blankenhorn D H (1966) Effect of phenobarbital on digitoxin metabolism. Clin Res 14: 160Google Scholar
  107. Johannessen S I, Strandjord R E, Munthe-Kaas A W (1977) Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine. Acta Neurol Scand 55: 506–512PubMedCrossRefGoogle Scholar
  108. Jordan B J, Shillingford J S, Steed K P (1976) Preliminary observations on the protein binding and enzyme-inducing properties of sodium valproate (Epilim). In: Legg NJ (ed) Clinical and pharmacological aspects of sodium valproate (Epilim) in the treatment of epilepsy, MCS consultants, Tunbridge Wells, pp 112–116Google Scholar
  109. Jubiz W, Meikle A W (1979) Alterations of glucocorticoid actions by other drugs and disease states. Clin Pharmacokinet 18: 113–121Google Scholar
  110. Jubiz W, Meikle A W, Levinson R A, Mizutani S, West C D, Tyler F H (1970) Effect of diphenylhydantoin on the metabolism of dexamethasone. N Engl J Med 283: 11–14PubMedCrossRefGoogle Scholar
  111. Kaldor A, Somogyi G, Debreczen L A (1975) Interaction of heart glycosides and pentobarbital. Int J Clin Pharmacol 12: 403Google Scholar
  112. Kapetenanovic I M, Kupferberg H J, Porter R J, Theodore W, Schulman E, Penry J K (1981) Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther 29: 480–486CrossRefGoogle Scholar
  113. Karch F E, Wardell W M, Dambly M, Gringeri A (1977) Effect of halofenate on the serum binding of phenytoin. Br J Clin Pharmacol 4: 625–626PubMedGoogle Scholar
  114. Kater R M H, Roggin G, Tobon F, Zieve P, Iber F L (1969) Increased rate of clearance of drugs from the circulation of alcoholics. Am J Med Sci 258: 35–39PubMedCrossRefGoogle Scholar
  115. Khoo K L, Mendels J, Rothbart M, Garland W A, Colburn W A, Min B H, Lucek R, Carbone J J, Boxenbaum H G, Kaplan S A (1980) Influence of phenytoin and phenobarbital on the disposition of a single oral dose of diazepam. Clin Pharmacol Ther 28: 368–375PubMedCrossRefGoogle Scholar
  116. Klotz V, Reimann I (1980) Delayed clearance of diazepam due to cimetidine. N Engl J Med 302: 1012–1014PubMedCrossRefGoogle Scholar
  117. Knott C, Hamshaw-Thomas A, Reynolds F (1982) Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy. Br Med J 284: 13–16CrossRefGoogle Scholar
  118. Koch K M, Ludwick B T, Levy R H (1981) Phenytoin-valproic acid interaction in rhesus monkey. Epilepsia 22: 19–25PubMedCrossRefGoogle Scholar
  119. Koch-Weser J, Sellers ES (1976) Binding of drugs to serum albumin. N Engl J Med 292: 311–316CrossRefGoogle Scholar
  120. Koranyi L, Gero L (1979) Influence of diphenylhydantoin on the effect of streptozotocin. Br Med J 1: 127PubMedCrossRefGoogle Scholar
  121. Koup J R, Gibaldi M, McNamara P, Hilligoss D M, Colburn W A, Bruck E (1978) Interaction of chloramphenicol with phenytoin and phenobarbital. Clin Pharmacol Ther 24: 571–575PubMedGoogle Scholar
  122. Kulshrestha V K, Thomas M, Wadsworth J, Richens A (1978) Interaction between phenytoin and antacids. Br J Clin Pharmacol 6: 177–179PubMedGoogle Scholar
  123. Kurata D, Wilkinson G R (1974) Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther 16: 355–362PubMedGoogle Scholar
  124. Kutt H (1971) Biochemical and genetical factors regulating Dilantin® metabolism in man. Ann NY Acad Sci 179: 704–722CrossRefGoogle Scholar
  125. Kutt H (1972) Diphenylhydantoin. Interactions with other drugs in man. In: Woodbury D M, Penry I K, Schmid R P (eds) Antiepileptic drugs. Raven, New York, pp 169–180Google Scholar
  126. Kutt H, Louis S (1972) Anticonvulsant drugs. II. Clinical pharmacological therapeutic aspects. CurrTher (Phila) 13: 58–82Google Scholar
  127. Kutt H, Winters W, McDowell F H (1966) Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy. Neurology 16: 594–602PubMedGoogle Scholar
  128. Kutt H, Brennan R, Dehejia H, Verebely K (1970) Diphenylhydantoin intoxication. A complication of isoniazid therapy. Am Rev Respir Dis 101: 377–384Google Scholar
  129. Labadarios D, Dickerson J W T, Parke D V, Lucas E G, Obuwa G H (1978) The effects of chronic drug administration on hepatic enzyme-induction and folate metabolism. Br J Clin Pharmacol 5: 167–173PubMedGoogle Scholar
  130. Lai A A, Levy R H, Cutler R E (1978) Time course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 24: 316–323PubMedGoogle Scholar
  131. Laizi V, Linnoila M, Seppala T, Himberg J J, Mattila M J (1979) Pharmacokinetic and pharmacodynamic interactions of diazepam with different alcoholic beverages. Eur J Clin Pharmacol 16: 262–270Google Scholar
  132. Lambie D G, Johnson R (1981) The effects of phenytoin on phenobarbitone and primidone metabolism. J Neurol Neurosurg Psychiatry 44: 148–151PubMedCrossRefGoogle Scholar
  133. Landay R A, Gonzalez M A, Taylor J C (1978) Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol 62: 27–29PubMedCrossRefGoogle Scholar
  134. Leonard R F, Knott P J, Rankin G O, Robinson D S, Melnick D E (1981) Phenytoin-salicy-late interaction. Clin Pharmacol Ther 29: 56–60PubMedCrossRefGoogle Scholar
  135. Lewis R (1966) Effect of barbiturates on anticoagulant therapy. N Engl J Med 274: 110Google Scholar
  136. Linnoila M, Viukari M, Vaisanen K, Auvinen J (1980) Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psych 137: 819–821Google Scholar
  137. Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM (1975) Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism. Clin Pharmacol Ther 17: 731–734PubMedGoogle Scholar
  138. Lunde P K M, Rane A, Yaffe S J, Lund L, Sjoqvist F (1970) Plasma protein bindings of diphenylhydantoin in man. Clin Pharmacol Ther 11: 846–855PubMedGoogle Scholar
  139. MacDonald M G, Robinson D S (1968) Clinical observations of possible barbiturate interference with anticoagulation. JAMA 204: 97–99PubMedCrossRefGoogle Scholar
  140. MacLeod S M, Sellers E M, Giles H G, Billings B J, Martin P R, Greenblatt D J, Marshman J A (1978) Interaction of disulfiram with benzodiazepines. Clin Pharmacol Ther 24: 583–589PubMedGoogle Scholar
  141. Makki K A, Perucca E, Richens A (1980) Metabolic effects of folic acid replacement therapy in folate-deficient epileptic patients. In: Johannessen S I, Morselli P L, Pippenger C E; Richens A, Schmidt D, Meinardi H (eds) Antiepileptic therapy. Advances in drug monitoring. Raven, New York, pp 391–396Google Scholar
  142. Marquis J F, Carruthers S G, Spence J D, Brownstone Y S, Toogood J H (1982) Phenytoin-theophylline interaction. N Engl J Med 307: 1189–1190PubMedCrossRefGoogle Scholar
  143. Mattson R H, Gallagher B B, Reynolds E H, Glass D (1973) Folate therapy in epilepsy. A controlled study. Arch Neurol 29: 78–81Google Scholar
  144. Mattson R H, Cramer J A, Williamson P C, Novelly R A (1978) Valproic acid in epilepsy: clinical and pharmacological effects. Ann Neurol 3: 20–25PubMedCrossRefGoogle Scholar
  145. Mattson G F, Mattson R H, Cramer J A (1982) Interaction between valproic acid and carbamazepine: an in vitro study of protein binding. Ther Drug Monit 4: 181–184PubMedCrossRefGoogle Scholar
  146. McLelland J, Jack W (1978) Phenytoin/dexamethasone interactions: a clinical problem. Lancet 1: 1096–1097PubMedCrossRefGoogle Scholar
  147. Mead P B, Gibson M, Schentag J J, Ziemniak J A (1982) Possible alteration of metronidazole metabolism by phenobarbital. N Engl J Med 306: 1490PubMedGoogle Scholar
  148. Meikle A W, Jubiz W, Matsukura S, West C D, Tyler F H (1969) Effect of diphenylhydantoin on the metabolism of metyrapone and release of ACTH in man. J clin Endocrinol Metab 29: 1553–1558PubMedCrossRefGoogle Scholar
  149. Mellett L B (1971) Chemistry and metabolism of cyclophosphamide. In: Vancil (ed) Immunosuppressive properties of cyclophosphamide. Mead and Johnson, Evansville, pp 6–34Google Scholar
  150. Mihaly G W, Vajda F J, Miles J L, Louis W J (1979) Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients. Eur J Clin Pharmacol 16: 23–29PubMedCrossRefGoogle Scholar
  151. Miller R R, Porter J, Greenblatt D J (1979) Clinical importance of the interaction of phenytoin and isoniazid. A report from the Boston collaborative drug surveillance program. Chest 75: 356–358Google Scholar
  152. Monks A, Richens A (1980) Effect of a single dose of sodium valproate on serum phenytoin concentration and protein binding in epileptic patients. Clin Pharmacol Ther 27: 89–95PubMedCrossRefGoogle Scholar
  153. Monks A, Boobis S, Wadsworth J, Richens A (1978) Plasma protein binding interaction between phenytoin and valproic acid in vitro. Br J Clin Pharmacol 6: 487–492PubMedGoogle Scholar
  154. Moody J P, Whyte S F, McDonald A J, Naylor G J (1977) Pharmacokinetic aspects of pro-triptyline plasma levels. Eur J Clin Pharmacol 11: 51–56PubMedCrossRefGoogle Scholar
  155. Morselli P, Rizzo M, Garattini S (1971) Interaction between phenobarbital and diphenylhydantoin in animals and in epileptic patients. Ann NY Acad Sci 179: 88–107PubMedCrossRefGoogle Scholar
  156. Murray F J (1962) Outbreak of unexpected reactions among epileptics taking isoniazid. Am Rev Respir Dis 86: 729–732PubMedGoogle Scholar
  157. Nanda R N, Johnson R H, Keogh H J, Lambie D G, Melville I D (1977) Treatment of epilepsy with clonazepam and its effect on other anticonvulsants. J Neurol Neurosurg Psychiatry 40: 538–543PubMedCrossRefGoogle Scholar
  158. Nappi J (1979) Warfarin and phenytoin interaction. Ann Intern Med 90: 852PubMedGoogle Scholar
  159. Nawishi S, Hathaway N (1982) Nomifensine pharmacokinetics in patients with epilepsy. Br J Clin Pharmacol 13: 295Google Scholar
  160. Nawishi S, Hathaway N, Turner P (1981) Interactions of anticonvulsant drugs with mianserin and nomifensine. Lancet 11: 870–871Google Scholar
  161. Neuvonen P J, Elonen E (1980) Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol 15: 51–57CrossRefGoogle Scholar
  162. Neuvonen PJ, Penttila O (1974) Interaction between doxycycline and barbiturates. Br Med J 1: 535–536PubMedCrossRefGoogle Scholar
  163. Neuvonen P J, Elfving S M, Elonen E (1978) Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. Eur J Clin Pharmacol 13: 213–218PubMedCrossRefGoogle Scholar
  164. Neuvonen P J, Lehtovaara R, Bardy A, Elonen E (1979) Antipyrine analgesics in patients on antiepileptic drug therapy. Eur J Clin Pharmacol 15: 263–268PubMedCrossRefGoogle Scholar
  165. Neuvonen P J, Kannisto H, Hirvisalo E L (1983) Effect of activated charcoal on absorption of tolbutamide and valproate in man. Eur J clin Pharmacol 24: 243–246PubMedCrossRefGoogle Scholar
  166. Notelovitz M, Tjapkes J, Ware M (1981) Interaction between oestrogen and Dilantin in a menopausal woman. N Engl J Med 304: 788–789PubMedCrossRefGoogle Scholar
  167. O’Brien LS, Orme Ml’E, Breckenridge AM (1978) Failure of antacids to alter the pharmacokinetics of phenytoin. Br J Clin Pharmacol 6: 176–177PubMedGoogle Scholar
  168. Ochs H R, Greenblatt D J, Roberts G M, Dengler H J (1981) Interaction of diazepam with antituberculosis drugs. Clin Pharmacol Ther 29: 270CrossRefGoogle Scholar
  169. Odar-Cederlof I, Borga O (1976) Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid. Clin Pharmacol Ther 20: 36–47PubMedGoogle Scholar
  170. Ohnhaus E E, Park B K, Colombo J P, Heizmann P (1979) The effect of enzyme-induction on diazepam metabolism in man. Br J Clin Pharmacol 8: 557–563PubMedGoogle Scholar
  171. Olanow C W, Finn A L, Prussak C (1981) The effects of salicylate on the pharmacokinetics of phenytoin. Neurology 31: 341–342PubMedGoogle Scholar
  172. Olesen O V (1967) The influence of disulfiram and calcium carbide on the serum diphenylhydantoin. Excretion of HPPH in the urine. Arch Neurol 16: 642–644PubMedGoogle Scholar
  173. Olesen O V, Jensen O N (1969) Drug interaction between sulthiame (Ospolot®) and phenytoin in the treatment of epilepsy. Dan Med Bull 16: 154–158PubMedGoogle Scholar
  174. Oppenheimer J H (1968) Role of plasma proteins in the binding, distribution and metabolism of the thyroid hormones. N Engl J Med 278: 1153PubMedCrossRefGoogle Scholar
  175. Orr J M, Abbott F S, Farrell K, Ferguson S, Sheppard I, Godolphin W (1982) Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects. Clin Pharmacol Ther 31: 642–649PubMedCrossRefGoogle Scholar
  176. Oxley J, Hedges A, Makki K A, Monks A, Richens A (1979) Lack of hepatic enzyme-inducing effect of sodium valproate. Br J Clin Pharmacol 8: 189–190PubMedGoogle Scholar
  177. Patel J H, Levy R H, Cutler R E (1980) Phenobarbital-valproic acid interaction in normal man. Clin Pharmacol Ther 27: 515–521PubMedCrossRefGoogle Scholar
  178. Patsalos P N, Lascelles P T (1977) Effect of sodium valproate on plasma protein binding of diphenylhydantoin. J Neurol Neurosurg Psychiatry 40: 570–574PubMedCrossRefGoogle Scholar
  179. Paxton J W (1980) Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects. Clin Pharmacol Ther 27: 170–178PubMedCrossRefGoogle Scholar
  180. Penttila O, Neuvonen P J, Aho K, Lehtovaara R (1974) Interaction between doxycycline and some antiepileptic drugs. Br Med J 2: 470–472PubMedCrossRefGoogle Scholar
  181. Perucca E (1978) Clinical consequences of microsomal enzyme-induction by antiepileptic drugs. Pharmacol Ther 2: 285–314Google Scholar
  182. Perucca E (1982) Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 7: 57–84PubMedCrossRefGoogle Scholar
  183. Perucca E, Richens A (1977) Interaction between phenytoin and imipramine. Br J Clin Pharmacol 4: 484–486Google Scholar
  184. Perucca E, Richens A (1979 a) Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. Br J Clin Pharmacol 7: 201–206Google Scholar
  185. Perucca E, Richens A (1979 b) Reduction of the oral availability of lignocaine by induction of first-pass metabolism in epileptic patients. Br J Clin Pharmacol 8: 21–31Google Scholar
  186. Perucca E, Richens A (1980 a) Water intoxication produced by carbamazepine and its reversal by phenytoin. J Neurol Neurosurg Psychiatry 43: 540–545Google Scholar
  187. Perucca E, Richens A (1980 b) Interpretation of drug levels: Relevance of plasma proteinGoogle Scholar
  188. binding. Ciba Found Symp 74:51–68Google Scholar
  189. Perucca E, Richens A ( 1980 c) Anticonvulsant drug interactions, In: Tyrer J (ed) The treatment of epilepsy. MTP, Lancaster, pp 95–128Google Scholar
  190. Perucca E, Richens A (1981) Drug interactions with phenytoin. Drugs 21: 120–137PubMedCrossRefGoogle Scholar
  191. Perucca E, Gatti G, Frigo G M, Crema A, Calzetti S, Visintini D (1978) Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 5: 495–499PubMedGoogle Scholar
  192. Perucca E, Hedges A, Makki K, Hebdige S, Wadsworth J, Richens A (1979) The comparative enzyme-inducing properties of antiepileptic drugs. Br J Clin Pharmacol 7: 414–415 PGoogle Scholar
  193. Perucca E, Hebdige S, Gatti G, Lecchini S, Frigo GM, Crema A (1980) Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 28: 779–789PubMedCrossRefGoogle Scholar
  194. Pfiasky K M, Sitar D S, Ogilvie R I (1977) Effect of phenobarbital on the disposition of intravenous theophylline. Clin Pharmacol Ther 22: 336–339Google Scholar
  195. Pisani F, Narbone MC, Fazio A, Crisafulli P, Primerano G, Amendola D’ Agostino A, Oteri G, DiPerri R (1984) Effect of viloxazine on serum carbamazepine levels in epileptic patients. Epilepsia 25: 482–485Google Scholar
  196. Pond S M, Kretzschmar K M (1981) Decreased bioavailability and increased clearance of meperidine during phenytoin administration. Clin Pharmacol Ther 29: 273Google Scholar
  197. Porter R J, Layzer R P (1975) Plasma albumin concentration and diphenylhydantoin binding in man. Arch Neurol 32: 298–303PubMedGoogle Scholar
  198. Powell J R, Nelson E, Conrad K A, Likes K, Byers J III, Perrier D (1981) Phenobarbital clearance, elimination with alkaline diuresis and bioavailability in adults. Clin Pharmacol Ther 29: 273Google Scholar
  199. Prescott L F, Critchley JAJ, Balali-Mood M, Pentland B (1981) Effect of microsomal enzyme-induction on paracetamol metabolism in man. Br J Clin Pharmacol 12: 149–154PubMedGoogle Scholar
  200. Pugh R N H, Geddes A M, Yeoman W B (1975) Interaction of phenytoin and chlorpheniramine. Br J Clin Pharmacol 2: 173–174PubMedGoogle Scholar
  201. Rambeck B (1979) Pharmacological interactions of methsuximide with phenobarbital and phenytoin in hospitalized epileptic patients. Epilepsia 20: 147–156PubMedCrossRefGoogle Scholar
  202. Rawlins MD, Collste P, Bertilsson L, Palmer L (1975) Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol 8: 91–96PubMedCrossRefGoogle Scholar
  203. Reed R C, Schwartz H J (1982) Phenytoin-theophylline-quinidine interaction. N Engl J Med 308: 724–725Google Scholar
  204. Reilly M J (1973) Drug information digest: methotrexate USP (amethopterin) and methotrexate sodium. Am J Hosp Pharm 30: 543–548Google Scholar
  205. Reynolds E H, Fenton G, Fenwick P, Johnson Al, Laundy M (1975) Interaction of phenytoin and primidone. Br Med J 2: 594–595PubMedCrossRefGoogle Scholar
  206. Richens A (1976) Drug treatment of epilepsy. Kimpton, London, pp 108–109Google Scholar
  207. Richens A, Houghton G W (1975) Effect of drug therapy on the metabolism of phenytoin. In: Schneider H, Janz D, Gardner-Thorpe C, Meinardi H, Sherwin AL (eds) Clinical pharmacology of antiepileptic drugs. Springer, Berlin Heidelberg New YorkGoogle Scholar
  208. Riegelman S, Rowland M, Epstein W L (1970) Griseofulvin-phenobarbital interaction in man. JAMA 213: 426–431PubMedCrossRefGoogle Scholar
  209. Rodin E A, De Sousa G, Haidukewych D, Lodhi R, Berchou R C (1981) Dissociation between free and bound phenytoin levels in presence of valproate sodium. Arch Neurol 38: 240–242PubMedGoogle Scholar
  210. Roe T F, Podosin RL, Blaskovics ME (1975) Drug interaction: diazoxide and diphenylhydantoin. J Pediatr 9: 285Google Scholar
  211. Rolan P A, Somogyi A W, Drew M J R, Cobain W G, South D, Bochner F (1983) Phenytoin intoxication during treatment with parenteral miconazole. Brit Med J 287: 1760CrossRefGoogle Scholar
  212. Rose J Q, Choi H K, Schentag J J, Kimbel W R, Jusko W J (1971) Intoxication caused by interaction of chloramphenicol and phenytoin. JAMA 237: 2630–2631CrossRefGoogle Scholar
  213. Rosenberry K R, Defusco C J, Mansmann H C Jr, McGeady S J (1983) Reduced theophylline half-life induced by carbamazepine therapy. J Pediat 102: 472–474PubMedCrossRefGoogle Scholar
  214. Ross J R Y, Buley L (1980) Interaction between carbamazepine and warfarin. Br Med J 280: 1415–1416PubMedCrossRefGoogle Scholar
  215. Routledge PA, Kitchell BB, Bjornsson TD, Skinner T, Linnoila M, Shand DG (1980) Diazepam and N-desmethyldiazepam redistribution after heparin. Clin Pharmacol Ther 27: 528–532PubMedCrossRefGoogle Scholar
  216. Routledge P A, Stargel W W, Finn A L, Barchowsky A, Shand D G (1981) Lignocaine disposition in blood in epilepsy. Br J clin Pharmacol 12: 663–666PubMedGoogle Scholar
  217. Ryan G M, Matthews P A (1970) Phenytoin metabolism stimulated by loxapine. Drug Intell clin Pharm 11: 428Google Scholar
  218. Sandor P, Sellers E M, Khouw V, Fan T (1980) Phenytoin disposition during alcohol ingestion and withdrawal. Clin Pharmacol Ther 27: 283Google Scholar
  219. Schmidt D (1975) The effect of phenytoin and ethosuximide on primidone metabolism inGoogle Scholar
  220. patients with epilepsy. J Neurol 209:115–123Google Scholar
  221. Sellers E M, Holloway M R (1978) Drug kinetics and alcohol ingestion. Clin Pharmacokinet 3: 440–452PubMedCrossRefGoogle Scholar
  222. Sellers E M, Naranjo C A, Giles H G, Frecker R L, Beeching R N (1980) Intravenous diazepam and oral ethanol interaction. Clin Pharmacol Ther 28: 638–645PubMedCrossRefGoogle Scholar
  223. Shader R I, Anastasios G, Greenblatt D J, Harmatz J S, Divoll Allen M (1978) Impaired absorption of desmethyldazepam from chlorazepate by magnesium-aluminium hydroxide. Clin Pharmacol Ther 24: 308–315PubMedGoogle Scholar
  224. Shahidi N T (1968) Acetophenetidin-induced methemoglobinemia. Ann NY Acad Sci 151: 822–831PubMedGoogle Scholar
  225. Skovsted L, Kristensen M, Hansen JM, Siersbaek-Nielsen K (1976) The effect of different oral anticoagulants on diphenylhydantoin and tolbutamide metabolism. Acta Med Scand 199: 513–515PubMedCrossRefGoogle Scholar
  226. Sjö O, Hvidberg E F, Naestoft J, Lund M (1975) Pharmacokinetics and side effects of clonazepam and its 7-amino metabolite in man. Eur J clin Pharmacol 8: 249–254PubMedCrossRefGoogle Scholar
  227. Solomon H, Abrams WB (1972) Interaction between digitoxin and other drugs in man. Am Heart J 83: 277–280PubMedCrossRefGoogle Scholar
  228. Solomon H M, Schrogie J J (1967) The effect of phenyramidol on the metabolism of diphenylhydantoin. Clin Pharmacol Ther 8: 554–556PubMedGoogle Scholar
  229. Solomon H M, Reich S, Spirt N, Abrams W B (1971) Interaction between digitoxin and other drugs in vitro and in vivo. Ann NY Acad Sci 179: 362–369PubMedCrossRefGoogle Scholar
  230. Sotaniemi E A, Pelkonen R O, Ahokas J, Pirttiaho H I, Ahlqvist J (1978) Drug metabolism in epileptics: in vivo and in vitro correlations. Br J clin Pharmacol 5: 71–76PubMedGoogle Scholar
  231. Sotaniemi E A, Anttila M, Pelkonen R O, Jarvensivu P, Sundquist H (1979) Plasma clearance of propranolol and sotalol and hepatic drug metabolizing enzyme activity. Clin Pharmacol Ther 26: 153–161PubMedGoogle Scholar
  232. Stambaugh J E, Wainer I W, Hemphill D M, Schwartz I (1977) A potentially toxic drug interaction between pethidine (meperidine) and phenobarbitone. Lancet 1: 398–399PubMedCrossRefGoogle Scholar
  233. Stambaugh J E, Wainer I W, Schwartz I (1978) The effect of phenobarbital on the metabolism of meperidine in normal volunteers. J Clin Pharmacol 18: 482–490PubMedGoogle Scholar
  234. Stenzel E, Boenigk H E, Rambeck B (1978) Methsuximide in the treatment of epilepsy. Epilepsia 19: 114Google Scholar
  235. Sutton G, Kupferberg HJ (1975) Isoniazid as an inhibitor of primidone metabolism. Neurology 25: 1179–1181PubMedGoogle Scholar
  236. Svendsen T L, Kristensen M B, Hansen J M, Skovsted L (1976) The influence of disulfiram on the half-life and clearance rate of diphenylhydantoin and tolbutamide in man. Eur J clin Pharmacol 9: 439–441CrossRefGoogle Scholar
  237. Syversen G B, Morgan J P, Weintraub M, Myers GJ (1977) Acetazolamide-induced interference with primidone absorption: case reports and metabolic studies. Arch Neurol 34: 80–84PubMedGoogle Scholar
  238. Taeuber K, Badian M, Brittel H F, Toyen T, Rypp W, Sitting W, Wihlein M (1979) Kinetic and dynamic interaction of clobazam and alcohol. Br J clin Pharmacol 7: 91–97SGoogle Scholar
  239. Telerman-Toppet N, Duret M E, Coers C (1981) Cimetidine interaction with carbamazepine. Ann Int Med 94: 544PubMedGoogle Scholar
  240. Träskman L, Asberg M, Bertilsson L, Cronholm B, Mellstrom B, Neckers LM, Sjoqvist F, Thoren P, Tybring G (1980) Plasma levels of chlorimipramine and its desmethyl-metabolite during treatment of depression. Clin Pharmacol Ther 6: 600–610Google Scholar
  241. Vesell E S, Passananti G T, Lee CH (1971) Impairment of drug metabolism by disulfiram in man. Clin Pharmacol Ther 21: 785–792Google Scholar
  242. Victor A, Lundbeg P O, Johansson E D B (1977) Induction of sex hormone binding globulin by phenytoin. Br Med J 2: 934–935PubMedCrossRefGoogle Scholar
  243. Vincent F M (1980) Phenothiazine-induced phenytoin intoxication. Ann Intern Med 93: 56–57PubMedGoogle Scholar
  244. Waddel WJ, Butler TC (1957) The distribution and excretion of phenobarbital. J Clin Invest 36: 1217–1226CrossRefGoogle Scholar
  245. Warren J W, Benmaman JD, Braxton B, Wannamaker BB, Levy RH (1980) Kinetics of a carbamazepine-ethosuximide interaction. Clin Pharmacol Ther 28: 646–651PubMedCrossRefGoogle Scholar
  246. Wasserman T H, Phillips T I, Vauraalte G, Urtasun R, Partington J, Kozid D, Schwade J G, Gangji D, Strong J M (1980) Neurotoxicity of misonidazole. Potential modifying role of phenytoin sodium and dexamethasone. Br J Radiol 53: 172–173Google Scholar
  247. Wesseling H, Mols-Thurkow I (1975) Interaction of diphenylhydantoin ( DPH) and tolbutamide in man. Eur J Clin Pharmacol 8: 75–78Google Scholar
  248. Wilenski A J, Levy R H, Troupin A S, Moretti-Ojemann L, Friel P (1978) Clorazepate kinetics in treated epileptics. Clin Pharmacol Ther 24: 22–30Google Scholar
  249. Windorfer A, Sauer W (1977) Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepine and dipropylacetate. Neuropediatrie 8: 29–41CrossRefGoogle Scholar
  250. Windorfer A, Sauer W, Gaedeke R (1975) Elevation of diphenylhydantoin and primidone serum concentration by addition of dipropylacetate, a new anticonvulsant drug. Acta Pediatr Scand 64: 771–772CrossRefGoogle Scholar
  251. Workman P, Bleehen N M, Wiltshire C R (1980) Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man; implications for possible reduced toxicity. Br J Cancer 41: 302–304PubMedCrossRefGoogle Scholar
  252. Wright J M, Stokes E F, Sweeney V P (1982) Isoniazid-induced carbamazepine toxicity and vice versa. A double drug interaction. N Engl J Med 307: 1225–1227Google Scholar
  253. Yokochi K, Yokochi A, Chiba K, Ishizaki T (1982) Phenytoin-allopurinol interaction: Michaelis-Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch-Nyhan syndrome. Ther Drug Monit 4: 353–358Google Scholar
  254. Zimmerman C L, Patel I H, Levy R H, Edwards D, Nelson S D, Hutchinson M (1981) Protein binding of valproic acid in the presence of elevated free fatty acids in patient and normal human serum. Epilepsia 22: 11–17PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • E. Perucca
  • A. Richens

There are no affiliations available

Personalised recommendations